// App-Quantinova.ai

2517 : A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.

Researchers

Presenter

  • Kerry Lynn Reynolds

Principal Investigators

  • Jose Baselga

  • Ezra E.W. Cohen

  • Se-Hoon Lee

  • Mauro Zucchetto

  • Xianbin Tian

  • Lily Delgado

  • Jian Li

  • Alex Morozov

  • Philippe L. Bedard

  • Donna M. Graham

  • Ana M. Gonzalez-Angulo

  • Ignacio Garrido-Laguna

  • Sunil Sharma

  • Chia-Chi Lin

  • Yung-Jue Bang

  • Maria Alsina

  • Josep Tabernero

Medical Centers

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Molecular Therapeutics Research Unit, Vall dHebron University Hospital, Barcelona, Spain

  • University of Utah Huntsman Cancer Institute, Salt Lake City, UTVall dHebron University Hospital, Barcelona, SpainThe University of Texas MD Anderson Cancer Center, Houston, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

  • Massachusetts General Hospital, Boston, MA

  • Novartis AG, Basel, Switzerland

  • Division of Oncology and Center for Investigational Therapeutics at Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Locations

  • Canada

  • Taiwan

  • Spain

  • Switzerland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Esophageal squamous carcinoma cell

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Breast cancer

  • Squamous cell carcinoma

  • Gastric Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • LJM716

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01598077

Sponsors

  • Novartis

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved